semaglutide and wound healing GLP-1 Agonists Orthopedic Surgery: A Review of Their Impact on Bone Metabolism, Healing, and Surgical Outcomes HBOT for Wound Healing -

Hyphema is bleeding inside the eye and collection of blood in the front part of the eye between the cornea and iris

It acts directly on neighboring -cells to inhibit the secretion of glucagon and can also indirectly influence -cells by inhibiting the secretion of other hormones.243 In the local islet environment, a high concentration of somatostatin creates an inhibitory milieu, further reducing the activity of -cells and the secretion of glucagon.244 Additionally, somatostatin can inhibit gastrointestinal activity, reducing the secretion of pancreatic enzymes and gastric acid, thereby indirectly decreasing the demand for glucagon.245,246 Hence, GLP-1 activates -cells and promotes somatostatin secretion, forming a multi-layered inhibitory mechanism that effectively reduces glucagon secretion

Infections: Even common illnesses can increase oxidative stress, which is why immune support is so important for this group

Can I take liraglutide and semaglutide at the same time

Key Takeaways Foundayo (orforglipron) is the first oral GLP-1 receptor agonist that can be taken any time of day without food or water restrictions FDA approved April 1, 2026 for chronic weight management Average weight loss in the ATTAIN-1 trial was 11.2% at 72 weeks at the highest dose less than injectable Wegovy (14.9%) or Zepbound (20.2%) Its small-molecule structure allows consistent absorption regardless of what is in the stomach Side effect profile is similar to other GLP-1 medications primarily gastrointestinal Starting cost is approximately $25/month with commercial insurance + Lilly savings card, $149/month self-pay for the lowest dose Best suited for patients with needle aversion, complicated schedules, or those who struggled with oral Wegovys fasting requirements Not recommended for patients already responding well to injectable GLP-1s Cannot be combined with other GLP-1 medications References Eli Lilly and Company

*Correspondence: Ana Karina Zambrano, [email protected] These authors have contributed equally to this work and share first authorship Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers